Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04153929
Recruitment Status : Recruiting
First Posted : November 6, 2019
Last Update Posted : April 8, 2021
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight.

Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are put into 7 groups. The participants in groups 1 to 6 get injections under the skin once or twice every week. Some participants get different doses of BI 456906 and other participants get placebo. Placebo injections look like the BI 456906 injections, but contain no medicine. Participants in group 7 get semaglutide injections every week. Semaglutide is another medicine for adults with type 2 diabetes.

During the study, the doctors regularly take blood samples from the participants and measure their body weight. The changes in blood sugar levels and body weight are compared between the groups. The doctors also check the general health of the participants.


Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: BI 456906 Drug: Placebo Drug: Semaglutide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 410 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.
Actual Study Start Date : April 30, 2020
Estimated Primary Completion Date : November 8, 2021
Estimated Study Completion Date : December 6, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dose group 1 Drug: BI 456906
Injection

Drug: Placebo
Injection

Experimental: Dose group 2 Drug: BI 456906
Injection

Drug: Placebo
Injection

Experimental: Dose group 3 Drug: BI 456906
Injection

Drug: Placebo
Injection

Experimental: Dose group 4 Drug: BI 456906
Injection

Drug: Placebo
Injection

Experimental: Dose group 5 Drug: BI 456906
Injection

Drug: Placebo
Injection

Experimental: Dose group 6 Drug: BI 456906
Injection

Drug: Placebo
Injection

Active Comparator: Dose group 7 (Semaglutide) Drug: Semaglutide
Injection




Primary Outcome Measures :
  1. Absolute change in HbA1c from baseline to 16 weeks [ Time Frame: Baseline, 16 weeks ]

Secondary Outcome Measures :
  1. The relative body weight change from baseline to 16 weeks (key secondary endpoint) [ Time Frame: Baseline, 16 weeks ]
  2. The absolute body weight change from baseline to 16 weeks. [ Time Frame: Baseline, 16 weeks ]
  3. The absolute change in waist circumference from baseline to 16 weeks [ Time Frame: Baseline, 16 weeks ]
  4. The percentage of patients with 5% or greater body weight loss from baseline to 16 weeks [ Time Frame: Baseline, 16 weeks ]
  5. The percentage of patients with 10% or greater body weight loss from baseline to 16 weeks [ Time Frame: Baseline, 16 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Signed and dated written informed consent in accordance with International conference on harmonization - Good clinical practice (ICH GCP) and local legislation.
  • Male and female patients 18 years to 75 years (both inclusive) of age on the day of signing informed consent.
  • Diagnosis of Type 2 diabetes mellitus (T2DM) at least 6 months prior to informed consent.
  • Glycosylated hemoglobin A1c (HbA1c) 7.0%-10.0% (both inclusive) at screening.
  • Treatment with a stable dose of metformin ≥ 1000mg/day for at least 3 months prior to screening.
  • Body mass index (BMI) 25 kg/m2-50 kg/m2 (both inclusive) at screening.
  • Women of childbearing potential must be ready and able to use highly effective methods of birth control.

Exclusion criteria:

  • Patients with type 1 diabetes.
  • Exposure to semaglutide, or other Glucagon-like-peptide 1 receptor (GLP-1R) agonists (including combination products) within 3 months prior to screening, or any previous exposure to BI 456906.
  • Any additional oral anti-hyperglycemic medication beyond metformin within 3 months prior to screening.
  • Use of insulin for glycemic control within 12 months prior to screening.
  • Resting Heart Rate >100 bpm or blood pressure ≥160/95 mmHg at screening.
  • A marked baseline prolongation of QT/QTc (Fridericia) interval or any other clinically significant Electrocardiogram (ECG) finding at screening.
  • Body weight change of +/- 5% or more in the past 3 months or on anti-obesity therapies at any time during the 6 months prior to screening.
  • Continuous oral pharmacotherapy to treat any clinical condition during the Trial. Following medications are allowed:

    • metformin, anti-hypertensives (any medication known to cause heart block or bradycardia such as beta-blockers, verapamil and diltiazem are excluded unless used to treat heart rate control or hypertension),
    • Hormone replacement therapy including thyroid hormone, lipid lowering, proton pump inhibitors, H2 blockers for Gastric esophageal reflux disease (GERD), analgesics,
    • sleep medications
    • antihistamines
    • selective Alpha receptor blocker for benign prostatic hyperplasia Patients must be on a stable dose for at least 3 months Prior to Screening
  • Any suicidal behavior in the past 2 years, any suicidal ideation of type 4 or 5 in the Columbia-suicide severity rating scale (C-SSRS) in the past 3 months at screening.
  • Chronic or relevant acute infections.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • Further exclusion criteria apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04153929


Contacts
Layout table for location contacts
Contact: Boehringer Ingelheim 1-800-243-0127 clintriage.rdg@boehringer-ingelheim.com

Locations
Show Show 87 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT04153929    
Other Study ID Numbers: 1404-0002
2019-002390-60 ( EudraCT Number )
First Posted: November 6, 2019    Key Record Dates
Last Update Posted: April 8, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https:// trials.boehringer-ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link http://trials.boehringeringelheim. com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access Criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
URL: https://trials.boehringer-ingelheim.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases